#USA #New York #Clinical Trials #Inato #AI Site Selection

Inato Revolutionizes Site Selection with AI Technology

Inato, a pioneering technology company, has recently launched advanced AI features designed to significantly enhance the site selection process for clinical trials. With its new platform capabilities, sponsors can now swiftly create and execute data-driven site selection scenarios. This enhancement is particularly timely, given the increasing complexity and competition within the clinical trial landscape.

Challenges in Traditional Site Selection

Site selection has long posed a considerable challenge for sponsors. The process demands extensive manual coordination across various geographies and reliance on spreadsheets and internal tools. Historically, sponsors had to invest months into validating assumptions and aligning all necessary stakeholders, often leading back to familiar, yet inadequate solutions like outdated site lists and historical data.

Despite various strategies aimed at improving this process, many of which revolve around purchasing site lists or building in-house tools, sponsors often found themselves reaching out to the same known sites—or worse, sites that were not even available. This inefficiency has become increasingly unsustainable as the number of clinical trials grows.

Recognizing this gap in the market, Inato has transformed the approach to site selection by leveraging its unparalleled global network of over 5,500 research sites. The platform enables sponsors to access rich and verified profiles from actively interested sites that are updated continuously based on real-time site engagement.

How Inato's AI Enhances Site Selection

Inato's AI site selection tool allows sponsors to navigate this complex decision-making process with ease. With a user-friendly interface, decision-makers can utilize plain language to interact with an AI analyst. This interaction can generate, edit, and compare site selection scenarios based on key trial objectives such as enrollment speed and patient access, as well as other customized criteria. This system stands apart from traditional methods by incorporating both comprehensive data and immediate site engagement metrics.

Kourosh Davarpanah, the co-founder and CEO of Inato, highlighted the dual advantage of this technology: "Data-driven site selection has often fallen short due to outdated information or a lack of emphasis on current site interest. Our AI analyst fills this void, allowing sponsors to merge their deep understanding of their trials with real-time data on qualified sites."

Key Benefits of Inato's AI Site Selection

Inato’s AI site selection offers numerous advantages for sponsors:

• - Global Site Engagement: By tapping into a vast network of engaged sites, decision-makers can easily choose the best mix of sites with verified data plus insights into site interest and activity.
• - Comprehensive Scenario Planning: The platform enables sponsors to assess all available sites through advanced filtering options, aligning them with crucial trial parameters, including proven performance and access to diverse patient populations.
• - Improved Speed and Efficiency: The AI tool can generate site selection scenarios within minutes. This newfound speed frees sponsors from tedious manual analysis and enables quicker engagement with the appropriate sites.

Inato’s commitment to revolutionizing clinical research is rooted in its mission to provide greater accessibility to trials. By streamlining the site selection process, Inato not only enhances the experience for sponsors but also aids in advancing medical research by ensuring diverse patient representation.

For further details on Inato’s AI site selection platform, potential users can visit their website or schedule a demo. This innovative leap positions Inato at the forefront of clinical trial technology, paving the way for future enhancements in the field. As clinical research evolves, tools like these will be crucial in ensuring that trials are conducted efficiently and inclusively.